In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please cancel claims 1-29 without prejudice to their presentation in another application, and add new claims 30-57 as follows:

1-29. (cancelled).

30. (new) An oral immediate release dosage form comprising N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide as the active compound, in the form of the free base or pharmaceutically acceptable salt, thereof, at least one disintegrant and/or at least one soluble filler, with or without one binder, and optionally other excipient.

31. (new) The oral immediated release dosage form according to claim 30 wherein the active compound is (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide.

32. (new) The oral immediated release dosage form according to claim 30 wherein the salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide is (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide monohydrobromide.

33. (new) The oral immediate release dosage form according to claim 30 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycollate, crospovidone, microcrystalline cellulose, low substituted hydropropyl cellulose, soy polysaccharide, starch, alginic acid, sodium alginate, polacrillin potassium, magnesium aluminium silicate, and amberlite resin.

34. (new) The oral immediate release dosage form according to claim 33 wherein the disintegrant is croscarmellose sodium.

35. (new) The oral immediate release dosage form according to claim 30 wherein the soluble filler is selected from the group consisting of lactose, sucrose, dextrose, mannitol, sorbitol, xylitol, maltose, maltodextrin, maltitol, lactitol, fructose, dextrate, and an inorganic salt.

36. (new) The oral immediate release dosage form according to claim 30 wherein the soluble filler is mannitol.

37. (new) The oral immediate release dosage form according to claim 30 wherein the binder is selected from the group consisting of hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, gelatine, polyethylene glycol, glycerylbehenate, glycerylmonostearate, ethylcellulose, ceratonia, hydroxy propylmethylcellulose, hydroxy ethylcellulose, polydextrose, polyethyleneoxide, zein, carboxy polymethylene, and carnauba wax, or a mixture thereof.

38. (new) The oral immediate release dosage form according to claim 37 wherein the binder is polyvinylpyrrolidone.

39. (new) The oral immediate release dosage form according to claim 30 wherein the other excipient is a lubricant, filler, or flow condition agent.

40. (new) The oral immediate release dosage form according to claim 39 wherein the lubricant is selected from the group consisting of magnesium stearate, calcium sterarate, zink stearate, carbomer, sodium stearyl fumarate, glyceryl monostearate, poloxamer, sodium benzoate, sodium lauryl sulphate, stearic acid, polyethylene glycol, and talc.

41. (new) The oral immediated release dosage form according to claim 39 wherein the filler is selected from the group consisting of calcium phosphate, starch, microcrystalline cellulose,

calcium sulphate, polyethylene glycol, calcium carbonate, magnesium carbonate, magnesium oxide, and kaolin.

42. (new) The oral immediate release dosage form according to claim 30 wherein the other excipient is sodium- or potassium carbonate or –bicarbonate alone or in combination with citric acid, ascorbic acid, or tartaric acid.

43. (new) The oral immediate release dosage form according to claim 39 wherein the flow condition agent is colloid silicon dioxide.

44. (new) The oral immediate release dosage form according to claim 30 wherein the ratio of active compound to disintegrant is from 6:1 to 1:2.

45. (new) The oral immediate release dosage form according to claim 30 wherein the ratio of active compound to disintegrant is from 3:1 to 1:1.

46. (new) The oral immediate release dosage form according to claim 30 wherein the weight ratio of active compound to binder is from 8:1 to 1:2.

47. (new) The oral immediate release dosage form according to claim 30 wherein the dosage form is in the form of a capsule or a tablet.

48. (new) The oral immediate release dosage form according to claim 30 whereby the dosage form has a mean dissolution profile *in vitro*, in 50 nM acetate buffer, pH of 5.5, using USP Paddle method at 75 rpm, such that at least 85% of the active compound is released within 30 minutes.

49. (new) An oral immediated release dosage form comprising 3 to 90 % (w/w) N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide, 0 to

20% (w/w) disintegrant, 0 to 80% (w/w) soluble filler, 1 to 10 % (w/w) binder, and up to 100% (w/w) other excipient.

50. (new) A method for the manufacture of an oral immediate release dosage form according to claim 30 comprising:

Method A, comprising the steps:

Ai) mixing the active compound with the disintegrant, soluble filler, binder, and optionally lubricant, filler and other excipient; and

Aii) forming the obtained dry powder mixture into a suitable solid dosage form;

or

Method B, comprising the steps:

Bi) mixing the active compound with the disintegrant, soluble filler, and optionally binder and other excipient;

Bii) granulating said mixture;

Biii) optionally drying or cooling the obtained granules;

Biv) mixing the granules with other excipient; and

Bv) filling the obtained dry powder mixture into suitable solid dosage form.

51. (new) A method of preventing and/or treating a disorder in the central nervous system of a mammal comprising contacting a mammal with an oral immediate release dosage form according to claim 30.

52. (new) The method of claim 51 wherein the disorder is a mood disorder, anxiety disorder, personality disorder, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbance, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorder, pathological aggression, schizophrenia, endocrine disorder, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorder, pain, or hypertension.

53. (new) The method of claim 51 wherein the disorder is major depressive disorder.

54. (new) The method of claim 51 wherein the disorder is urinary incontinence, vasospasm, or growth control of a tumor.

55. (new) The method of claim 51 wherein the disorder is a 5-hydroxytryptamine mediated disorder.

56. (new) The oral immediate release dosage form according to claim 30 whereby the dosage form upon administration provides t_{max} for (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide monohydrobromide between 3 to 7 hours.

57. (new) A method of preparing an oral immediate release dosage form of an active compound that forms an agglomerate upon contact with water, at acidic, neutral or basic pH comprising formulating the active compound with a disintegrant.